Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

GSK (NYSE:GSK) has received Chinese regulatory ... The drug is already approved in China as an add-on maintenance treatment for people aged 12 years and older with severe eosinophilic asthma ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...

GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...

GSK is enlisting the aid of China’s Chongqing Zhifei Biological Products (Zhifei) to drive sales of its most important vaccine, Shingrix, in China over the next few years, and may also call upon ...

GlaxoSmithKline has announced plans to collaborate with China’s Xiamen Innovex on a potential vaccine to treat the COVID-19 coronavirus. The companies are testing a recombinant protein-based ...

Chinese regulators are investigating the quality of domestic generic drugs after a rare public backlash against a cost-cutting campaign that prioritised their use in the national healthcare system but ...

GSK plc announced that the China National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with ...

Alphabet also remains a popular pick among hedge fund managers. According to Insider Monkey data, 202 hedge fund investors ...